Safety and immunogenicity of a three-component blood-stage malaria vaccine in adults living in an endemic area of Papua New Guinea

Details

Serval ID
serval:BIB_6CE031246808
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Safety and immunogenicity of a three-component blood-stage malaria vaccine in adults living in an endemic area of Papua New Guinea
Journal
Vaccine
Author(s)
Genton  B., Al-Yaman  F., Anders  R., Saul  A., Brown  G., Pye  D., Irving  D. O., Briggs  W. R., Mai  A., Ginny  M., Adiguma  T., Rare  L., Giddy  A., Reber-Liske  R., Stuerchler  D., Alpers  M. P.
ISSN
0264-410X (Print)
Publication state
Published
Issued date
05/2000
Volume
18
Number
23
Pages
2504-11
Notes
Clinical Trial
Clinical Trial, Phase I
Controlled Clinical Trial
Journal Article
Research Support, Non-U.S. Gov't --- Old month value: May 22
Abstract
A Phase I safety and immunogenicity study with a three-component blood-stage malaria vaccine was conducted in adult male subjects living in an endemic area of Papua New Guinea. The preparations were recombinant proteins which corresponded to parts of the two merozoite surface proteins of Plasmodium falciparum (MSP1 and 2), and of the ring-infected erythrocyte surface antigen (RESA). The three proteins were emulsified with the adjuvant Montanide ISA720. Ten subjects were injected twice (four weeks apart) with the vaccine formulation and two with the adjuvant alone. Mild pain at the site of injection was reported by about half of the subjects but no systemic reaction related to the formulation occurred. There was a sharp rise in geometric mean stimulation index after the second dose compared to baseline for MSP1 and RESA, while the rise was small for MSP2. Geometric mean antibody titres increased for MSP1 during the study, whereas they hardly changed for MSP2 and RESA. The vaccine formulation was safe when used in an already immune population. The vaccine induced good cellular responses, especially for MSP1 and RESA. Boosting of humoral responses was weak, probably because of high baseline antibody levels.
Keywords
Adjuvants, Immunologic Adult Animals Antibodies, Protozoan/*biosynthesis/immunology Antigens, Protozoan/*immunology Cytokines/blood Cytotoxicity, Immunologic Humans Immunization, Secondary Malaria Vaccines/adverse effects/*immunology Malaria, Falciparum/prevention & control Male Mannitol/analogs & derivatives/immunology Merozoite Surface Protein 1/*immunology Middle Aged Oleic Acids/immunology Papua New Guinea Plasmodium falciparum/growth & development/*immunology Protozoan Proteins/*immunology Safety T-Lymphocytes/immunology *Vaccination/adverse effects
Pubmed
Web of science
Create date
28/01/2008 11:49
Last modification date
20/08/2019 14:26
Usage data